Premium theater ticket sales aren't as robust as Hollywood and Wall Street would like them to be. Imax stock fell a dramatic 14% this week and is currently trading at $26.72 at the time of this writing.

This week's opening of 3-D space drama "Gravity" was supposed to be a boon for the giant screen exhibitor and ticket sales for the Imax screenings have been solid. However, analysts' overall outlook of the company has been sour and investors have responded with equal negativity.

On Wednesday, analyst Michael Pachter of Wedbush dropped his target price on Imax to $28 per share due to weak results from the company's third quarter. Films like "Elysium," "Pacific Rim," and "Riddick" all underperformed for the studios, which meant that Imax also suffered.

Mark Hickey, an analyst at Benchmark, gave Imax a "hold" rating and set his target price at $29.42. Hickey noted that the upcoming slate of 3-D films, which include retreads like "Godzilla," "Frankenstein" and a "RoboCop" reboot won't be exciting enough for audiences to shell out for premium tickets. Many in Hollywood have criticized fellow studio heads for releasing subpar 3-D or Imax films which turn audiences off to the premium theatrical experience.

Hickey also pointed out that Imax isn't building as many theaters and that slow growth for the company will yield little gain for investors. Pacter agrees when it comes to Imax's expansion plans.